PepGen (PEPG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting will be held virtually on June 18, 2026, with voting on director elections and auditor ratification.
Proxy materials are distributed electronically to reduce costs and environmental impact.
Only stockholders of record as of April 21, 2026, are eligible to vote.
The company remains an emerging growth company and provides scaled disclosures under the JOBS Act.
Voting matters and shareholder proposals
Stockholders will vote on electing three Class I directors for three-year terms and ratifying KPMG LLP as the independent auditor for 2026.
Board recommends voting FOR all director nominees and auditor ratification.
Shareholders may submit proposals for the 2027 meeting between February 18, 2027, and March 20, 2027.
Proposals for inclusion in the 2027 proxy must be received by December 30, 2026.
Board of directors and corporate governance
The board is divided into three staggered classes, each serving three-year terms.
Nominees for Class I directors: Howard Mayer, Joshua Resnick, and Lisa Wyman, all with significant industry experience.
Board committees include audit, compensation, and nominating/governance, all composed of independent directors.
The chair and CEO roles are separated to enhance governance.
Annual board and committee self-evaluations are conducted.
Latest events from PepGen
- PGN-EDODM1 delivers strong splicing correction and safety in DM1, with pivotal data ahead.PEPG
Company presentation12 May 2026 - Executive agreements updated and FREEDOM2 trial advanced, with cash runway into 2H 2027.PEPG
Q1 202612 May 2026 - Virtual meeting to elect directors and ratify KPMG LLP as auditor, with board support for both.PEPG
Proxy filing28 Apr 2026 - PGN-EDODM1 shows strong efficacy and safety in DM1, with pivotal data expected by 2027.PEPG
Company presentation19 Apr 2026 - PGN-EDODM1 at 5 mg/kg showed strong safety and splicing correction, supporting dose escalation.PEPG
Study update13 Apr 2026 - Record splicing improvements and robust safety data drive global DM1 trial progress.PEPG
Leerink Global Healthcare Conference 202610 Mar 2026 - PGN-EDODM1 shows best-in-class splicing correction and strong safety in DM1 trials.PEPG
Company presentation4 Mar 2026 - PGN-EDODM1 delivers best-in-class splicing correction and strong safety in DM1 trials.PEPG
corporate presentation4 Mar 2026 - Advancing DM1 clinical program with strong cash position and key data readouts expected in 2026.PEPG
Q4 20254 Mar 2026